Can IVIg and efgartigimod help a man with Graves disease and Guillain-Barré syndrome?
A specific case report describes a 33-year-old man who had motor-predominant Guillain-Barré syndrome and Graves disease. He also had thyroid cancer. His symptoms came back repeatedly, but he responded well to intravenous immunoglobulin (IVIg) and efgartigimod. Later, removing his thyroid gland helped stabilize his neurological symptoms.
What the research says
The patient had high levels of thyroid autoantibodies and immune markers like interleukin-6 and interleukin-8, which fit the pattern of Graves disease. His nerve tests showed demyelination typical of Guillain-Barré syndrome, but he had a relapsing course rather than a single episode. This suggests ongoing immune system activation was driving his symptoms 1.
He received treatment with IVIg, which provides antibodies to calm the immune response, and efgartigimod, which blocks a protein called FcRn to help clear excess antibodies. Both treatments helped control his condition. However, doctors found he had papillary thyroid cancer with a BRAF mutation. After he had his thyroid removed, his neurological symptoms stabilized 1.
Other studies discuss Graves disease and immune changes in different contexts, such as how certain genetic markers affect drug reactions or how pandemic-related factors might shift thyroid disease rates. These do not directly address the use of IVIg or efgartigimod for this specific combination of conditions 23.
What to ask your doctor
- Could my relapsing Guillain-Barré syndrome be linked to my Graves disease or thyroid cancer?
- Would IVIg or efgartigimod be appropriate options for managing my immune-driven symptoms?
- If I have thyroid cancer, how might removing my thyroid affect my neurological recovery?
- What signs should I watch for to know if my immune system is becoming active again?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.